Chris Schaumburg, Ph.D., M.B.A., is a business strategy leader and immunologist with over 15 years of cross-functional experience spanning business development, strategy, scientific research, drug discovery and clinical development. Before leading corporate affairs, Dr. Schaumburg held the position of Vice President of Business Development at Mirador. Before joining Mirador, he was the Vice President of Pipeline Strategy at Prometheus Biosciences, where he led portfolio strategy from March 2022 through the company’s sale to Merck in 2023. Prior to that, Dr. Schaumburg served as Vice President Head of Business Development at Urovant Sciences, Inc., where he worked from 2018-2022, through the company’s IPO and take-private merger for a significant premium with Sumitomo Dainippon.

Dr. Schaumburg began his career in scientific research, with a focus on inflammation and autoimmune disease. Among his prior roles, Dr. Schaumburg was co-director of the Inflammation Research Program at Allergan, Inc. where he focused on drug discovery and strategy in the company’s largest therapeutic area.

He holds a Ph.D. from the University of California, Irvine, and an M.B.A. from the University of California, Los Angeles (UCLA) Anderson School of Management.